When: $395 close-based (below 9/15 swing low, ~2.7% from spot)

Then: Exit remaining position

When: $356 weekly close (200 SMA structural break)

Then: No further trim below 60-70% sizing; reassess thesis

HOLD at benchmark weight; accept max 10-15% trim only if price closes below $401.50 on volume; implement protective collar instead of position cuts

• AMGN trading at $406, 13.6% above 200-day SMA ($357); long-term uptrend intact
• Forward P/E of 16.6x with implied EPS $24.45 vs TTM $16.08 (52% growth embedded)
• Beta of 0.43 provides defensive characteristics in macro environment with 10-year at 2007 highs
• Dividend yield 2.48% on $219B market cap = $5B+ annual cash return; grown every year for over a decade
• Free cash flow TTM of $8.65 billion demonstrates financial strength
• 50-day SMA reclaimed at $401.56 on consecutive closes; 10 EMA at $395.96 below price
• RSI at 52 neutral (not bearish); MACD histogram contracting from deeply negative toward zero
• OASIZ 302 is a weeks-to-months event, not imminent; selling now is premature hedging
• Q4 2025 EPS of $2.45 vs Q3's $5.93 reflects anomalous quarter, not baseline
• Receivables up 20% vs revenue up 8% over four quarters is a watch item but doesn't warrant 30-50% cut

→ vs aggressive: 50-day reclaim at only 1.1% above average is a low-risk entry, not a high-risk exit signal; 10 EMA well below price confirms short-term momentum is positive

→ vs aggressive: AMGN traded up 7.9% on OASIZ 301 but the stock is at $406 versus Jefferies' $410 target—not at a confirmed top; 52-week high is $447

→ vs aggressive: Forward P/E of 16.6x is reasonable given 52% earnings growth embedded in the multiple; JNJ, MRK, PFE face patent cliffs and slower growth, making direct comparison flawed

→ vs aggressive: OASIZ 302 is weeks away, not imminent; selling 30-50% now to 'de-risk' a distant binary locks in losses while momentum repairs

→ vs aggressive: 2.48% dividend yield is not a 'slow leak'—it's over $5B annual cash return with decade-plus of growth; forfeiting this carry for unnamed 'cleaner setups' is not risk management

→ vs aggressive: Aggressive plan is market timing; conservative discipline manages position size relative to conviction, not binary event speculation

→ vs aggressive: Q3 2025 EPS of $5.93 was likely one-time tax benefit or revenue pull-forward; treating Q4's $2.45 as new normal is directional bias

Execute a measured 15-20% position trim triggered by technical invalidation (close below $401.50 on above-average volume), paired with protective puts on approximately one-third of the remaining position

• Technical setup is genuinely 'coin-flip' - 50 SMA reclaim at 1.1% above average with negative MACD is inconclusive; some de-risking warranted but not aggressive blast-cut
• Aggressive analyst conflates single-day 7.9% post-readout move with multi-year pipeline thesis; dazodalibep is potentially first-in-class in zero-approved disease-modifying indication
• Conservative analyst's collar ($390 put / $430 call) explicitly caps upside and is not 'free insurance' - it's a defined-range trade dressed as neutrality
• DSO receivables grew from $8.49 billion to $10.23 billion over four consecutive quarters - structural trend, not seasonal blip
• Forward P/E of 16.6 against 52% implied EPS growth yields PEG of approximately 0.3, not the 2.45 trailing PEG the aggressive analyst implicitly invokes
• OASIZ 302 catalyst is weeks to months away - time to let price action guide positioning rather than pre-committing to 30-50% cut today
• Proposed trim: 15-20% of existing position (half of aggressive analyst's 30-50% recommendation)
• Trim trigger: Close below $401.50 on above-average volume to invalidate 50-day reclaim
• Post-trim target weight: 85-90% of benchmark (vs. original trader's proposed 60-70%)
• Options approach: Buy 60-90 day puts at $390 strike on ~1/3 of remaining position - skip full collar to avoid capping upside
• Hard exit stop at $395 on single-day gap-down basis; tighten closing invalidation trigger to $401.50
• Fundamentals support defensive overweight to large-cap pharma with cash flow and dividends - going aggressively underweight throws away real portfolio value
• Jefferies target of $410 explicitly built in assumption that OASIZ 302 confirmation needed for further upside

→ vs aggressive: Core mistake is treating 7.9% post-readout move as if entire dazodalibep thesis is now fully discounted - that's one-day-window analysis, not pipeline analysis; also conflating TTM-anchored PEG with forward-anchored argument (apples to oranges)

→ vs aggressive: Prescription of selling 30-50% of position is overshooting; fighting the timing structure of a binary catalyst event weeks to months away when technical report itself calls 406 area a 'coin-flip zone'

→ vs conservative: Collar recommendation ($390 put / $430 call) is not 'free insurance' - it explicitly caps upside at the call strike, locking in only a fraction of upside if OASIZ 302 confirms and stock moves toward 447 or higher

→ vs conservative: Too dismissive of DSO trend; 20% receivables growth against 8% revenue growth over four consecutive quarters is structural, not seasonal; combined with Q4 2025 EPS step-down to 2.45 vs 5.93 in Q3, bears have a real point on uneven operating momentum

→ vs conservative: Using confirmation discipline to justify inaction while binary OASIZ 302 catalyst approaches - by the time Q3 2026 earnings print in late October, the readout may already have occurred

→ vs conservative: Long-term trend argument (13.6% above 200 SMA) is technically true but practically irrelevant to near-term entry point question; you can be in long-term uptrend and still face 10-15% pullback from binary event